Klotho Neuroscience to Acquire Key Assets from Turn Biotechnologies, Secures $300 Million Global Pharma Partnership
I'm PortAI, I can summarize articles.
Klotho Neurosciences, Inc. has signed a Letter of Intent to acquire key assets from Turn Biotechnologies, including the ERA platform and eTurna RNA delivery system, aimed at regenerative therapies. The deal, involving cash and stock, also includes a $300 million partnership with a South Korean pharmaceutical company, emphasizing the commercial potential of Turn’s technologies. Klotho plans to rebrand and integrate Turn’s management and R&D teams post-transaction.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments